Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleCLINICAL INVESTIGATIONS

Targeting, Toxicity, and Efficacy of 2-Step, Pretargeted Radioimmunotherapy Using a Chimeric Bispecific Antibody and 131I-Labeled Bivalent Hapten in a Phase I Optimization Clinical Trial

Françoise Kraeber-Bodéré, Caroline Rousseau, Caroline Bodet-Milin, Ludovic Ferrer, Alain Faivre-Chauvet, Loïc Campion, Jean-Philippe Vuillez, Anne Devillers, Chien-Hsing Chang, David M. Goldenberg, Jean-François Chatal and Jacques Barbet
Journal of Nuclear Medicine February 2006, 47 (2) 247-255;
Françoise Kraeber-Bodéré
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Rousseau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline Bodet-Milin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ludovic Ferrer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alain Faivre-Chauvet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loïc Campion
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Philippe Vuillez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Devillers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chien-Hsing Chang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David M. Goldenberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-François Chatal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacques Barbet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 47 no. 2 247-255
PubMed 
16455630

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication July 4, 2005
  • Accepted for publication October 5, 2005
  • Published online February 1, 2006.

Copyright & Usage 
© 2006 by Society of Nuclear Medicine

Author Information

  1. Françoise Kraeber-Bodéré, MD, PhD 1 , 2 ,
  2. Caroline Rousseau, MD 1 ,
  3. Caroline Bodet-Milin, MD 1 ,
  4. Ludovic Ferrer, MD 1 ,
  5. Alain Faivre-Chauvet, PhD 1 , 2 ,
  6. Loïc Campion, MD 1 ,
  7. Jean-Philippe Vuillez, MD, PhD 3 ,
  8. Anne Devillers, MD 4 ,
  9. Chien-Hsing Chang, PhD 5 ,
  10. David M. Goldenberg, ScD, MD 5 , 6 ,
  11. Jean-François Chatal, MD, PhD 1 , 2 and
  12. Jacques Barbet, PhD 2
  1. 1Nuclear Medicine Department, René Gauducheau Cancer Center, Nantes, France; 2Oncology Research Department, INSERM U601, Nantes, France; 3Nuclear Medicine Department, Michalon Hospital, Grenoble, France; 4Nuclear Medicine Department, Eugène Marquis Cancer Center, Rennes, France; 5IBC Pharmaceuticals, Inc., Morris Plains, New Jersey; and 6Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey
  1. For correspondence or reprints contact: Françoise Kraeber-Bodéré, MD, PhD, Oncology Research Department, INSERM U601, Institut de Biologie, 9 quai Moncousu, 44093 Nantes Cedex 1, France. E-mail: francoise.bodere{at}chu-nantes.fr
View Full Text

Statistics from Altmetric.com

Cited By...

  • 89 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: February 2006 to April 2025

AbstractFullPdf
Feb 2006894188
Mar 2006402431
Apr 2006201516
May 200614512
Jun 20061423
Jul 2006101215
Aug 2006467
Sep 20061243
Oct 20061943
Nov 200618811
Dec 20061462
Jan 20071087
Feb 20076129
Mar 200773025
Apr 2007173215
May 2007122412
Jun 2007192216
Jul 2007101311
Aug 200710218
Sep 200791411
Oct 200751614
Nov 200711710
Dec 2007171712
Jan 200812117
Feb 2008876
Mar 200871311
Apr 200861412
May 20084137
Jun 2008101712
Jul 2008232214
Aug 200818154
Sep 2008101611
Oct 2008152014
Nov 2008102215
Dec 200872716
Jan 20091376
Feb 2009684
Mar 200914133
Apr 20091293
May 200992116
Jun 200915236
Jul 200917246
Aug 200910175
Sep 20093165
Oct 2009391410
Nov 200948146
Dec 20091468
Jan 20108116
Feb 2010875
Mar 2010373
Apr 20104164
May 201018165
Jun 201012116
Jul 20101852
Aug 20102156
Sep 201014109
Oct 2010131
Nov 20108108
Dec 20106109
Jan 20117106
Feb 201181711
Mar 201191711
Apr 20117205
May 201123289
Jun 201110154
Jul 2011201411
Aug 2011171612
Sep 2011212014
Oct 2011231517
Nov 20113074
Dec 2011331412
Jan 2012231313
Feb 20122476
Mar 201224106
Apr 201235102
May 201235117
Jun 20122373
Jul 2012191411
Aug 201222196
Sep 201221177
Oct 201230114
Nov 2012271510
Dec 201241279
Jan 201336149
Feb 20132599
Mar 2013291014
Apr 201318138
May 2013381811
Jun 2013132413
Jul 2013211010
Aug 20131973
Sep 20131952
Oct 2013620
Nov 2013997
Dec 20131412
Jan 20141022
Feb 20141494
Mar 201413104
Apr 2014101815
May 201424176
Jun 20141445
Jul 20141068
Aug 201413178
Sep 2014231610
Oct 201421468
Nov 201422366
Dec 201411101
Jan 20151042
Feb 20151494
Mar 20152562
Apr 2015211510
May 20152792
Jun 20151276
Jul 2015808
Aug 20151194
Sep 20151094
Oct 201534106
Nov 201518167
Dec 201550333
Jan 201658108
Feb 201623810
Mar 20161945
Apr 20162728
May 201612510
Jun 20162352
Jul 20162567
Aug 201618811
Sep 2016365
Oct 2016797
Nov 2016974
Dec 201612115
Jan 201722198
Feb 2017372
Mar 201741351
Apr 201761162
May 20178985
Jun 201751351
Jul 201791068
Aug 201731064
Sep 20176843
Oct 20173934
Nov 20177866
Dec 201711436
Jan 20187817
Feb 20189124
Mar 201810217
Apr 20181145
May 201810277
Jun 20187123
Jul 20186183
Aug 20183144
Sep 20186183
Oct 201813326
Nov 201815323
Dec 20182347
Jan 20196254
Feb 20196161
Mar 201916226
Apr 2019784
May 2019443
Jun 2019823
Jul 20196134
Aug 20194133
Sep 2019346
Oct 20191436
Nov 2019757
Dec 2019845
Jan 2020723
Feb 2020732
Mar 20201373
Apr 2020712
May 2020768
Jun 2020766
Jul 2020541
Aug 2020645
Sep 20201312
Oct 20201359
Nov 20201135
Dec 20208106
Jan 2021484
Feb 20214195
Mar 202151914
Apr 20216196
May 202151513
Jun 2021594
Jul 2021576
Aug 2021663
Sep 2021470
Oct 2021394
Nov 2021265
Dec 202114189
Jan 2022221712
Feb 2022394
Mar 20223103
Apr 2022585
May 2022435
Jun 2022687
Jul 20222116
Aug 20225166
Sep 20222155
Oct 2022575
Nov 20225133
Dec 2022683
Jan 2023101210
Feb 202310178
Mar 20236322
Apr 20234224
May 20238114
Jun 202381711
Jul 20234126
Aug 2023277
Sep 2023394
Oct 20234206
Nov 20233123
Dec 20234362
Jan 20245159
Feb 20241141
Mar 2024322
Apr 202451288
May 202451199
Jun 20245153
Jul 20245233
Aug 202495417
Sep 202443816
Oct 202410198
Nov 20241142
Dec 20247206
Jan 20252248
Feb 2025610510
Mar 202544515
Apr 202534518
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 47 (2)
Journal of Nuclear Medicine
Vol. 47, Issue 2
February 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Targeting, Toxicity, and Efficacy of 2-Step, Pretargeted Radioimmunotherapy Using a Chimeric Bispecific Antibody and 131I-Labeled Bivalent Hapten in a Phase I Optimization Clinical Trial
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Targeting, Toxicity, and Efficacy of 2-Step, Pretargeted Radioimmunotherapy Using a Chimeric Bispecific Antibody and 131I-Labeled Bivalent Hapten in a Phase I Optimization Clinical Trial
Françoise Kraeber-Bodéré, Caroline Rousseau, Caroline Bodet-Milin, Ludovic Ferrer, Alain Faivre-Chauvet, Loïc Campion, Jean-Philippe Vuillez, Anne Devillers, Chien-Hsing Chang, David M. Goldenberg, Jean-François Chatal, Jacques Barbet
Journal of Nuclear Medicine Feb 2006, 47 (2) 247-255;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Targeting, Toxicity, and Efficacy of 2-Step, Pretargeted Radioimmunotherapy Using a Chimeric Bispecific Antibody and 131I-Labeled Bivalent Hapten in a Phase I Optimization Clinical Trial
Françoise Kraeber-Bodéré, Caroline Rousseau, Caroline Bodet-Milin, Ludovic Ferrer, Alain Faivre-Chauvet, Loïc Campion, Jean-Philippe Vuillez, Anne Devillers, Chien-Hsing Chang, David M. Goldenberg, Jean-François Chatal, Jacques Barbet
Journal of Nuclear Medicine Feb 2006, 47 (2) 247-255;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • Radioimmunotherapy of Solid Tumors: The Promise of Pretargeting Strategies Using Bispecific Antibodies and Radiolabeled Haptens
  • PubMed
  • Google Scholar

Cited By...

  • Pretargeting: A Path Forward for Radioimmunotherapy
  • Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis
  • Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy
  • Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA
  • "Catch-and-Release" Anti-Carcinoembryonic Antigen Monoclonal Antibody Leads to Greater Plasma and Tumor Exposure in a Mouse Model of Colorectal Cancer
  • Pretargeted Imaging and Therapy
  • Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry
  • Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial
  • Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement
  • Convergent Potency of Internalized Gelonin Immunotoxins across Varied Cell Lines, Antigens, and Targeting Moieties
  • Pretargeted 177Lu Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colonic Tumors in Mice
  • An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector
  • Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting
  • Pathology Underrates Colon Cancer Extranodal and Nodal Metastases; Ex vivo Radioimmunodetection Helps Staging
  • Pretargeted Anti-Carcinoembryonic-Antigen Radioimmunotherapy for Medullary Thyroid Carcinoma
  • Radioimmunotherapy of Solid Tumors: The Promise of Pretargeting Strategies Using Bispecific Antibodies and Radiolabeled Haptens
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
Show more Clinical Investigations

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire